SMMT
Summit Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.63
−4.81%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$15.39
From 52W high−44.54%
Volume4.30M
Market cap$11.67B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 16, 2026
Open
$15.39
From 52W high
−44.54%
Volume
4.30M
Market cap
$11.67B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−12.9x
P/E (TTM)
—
RSI (14)
39.6
MomentumView details →
1D Return
−4.81%
YTD Return
−15.10%
SummaryUpdated Jun 1, 2026
Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company founded in 2003 and headquartered in Cambridge, Massachusetts. Originally focused on developing treatments for infectious diseases, the company underwent a strategic transformation in 2022 when it pivoted entirely to oncology. Summit acquired the rights to develop and commercialize ivonescimab, a promising cancer immunotherapy, through a landmark $500 million licensing agreement with Chinese biotech company Akeso. The company is now focused exclusively on advancing this bispecific antibody through late-stage clinical trials for various cancer indications, particularly non-small cell lung cancer.
Similar companies
Latest newsMore news →
AstraZeneca and Daiichi Sankyo entered into a clinical collaboration with Summit Therapeutics to test Datroway in combination with ivonescimab across multiple tumour types, including lung and breast cancers.17d agoSummit Therapeutics shares surged 23%, marking their largest intraday gain since April 2025.19d agoAkeso shares surged as much as 15.65% to HK$106.4 in morning trading after its overseas partner Summit Therapeutics received a US$2 billion strategic investment from AstraZeneca.20d ago